Cardinal Health — Aug 12, 2025 release
Fiscal 2025 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000721371-25-000075
Showing in the filing
Non-GAAP effective tax rate
“22.0% - 24.0%”
Period
FY2026
Measure
Company-defined measure
Source
Prose
All guidance in this release · 13
Non-GAAP EPS for FY2026
“$9.30 to $9.50”
Non-GAAP diluted earnings per share for FY2026
“$9.30 to $9.50”
Pharmaceutical and Specialty Solutions segme… for FY2026
“11% to 13% growth”
Global Medical Products and Distribution seg… for FY2026
“2% to 4% growth”
Global Medical Products and Distribution seg… for FY2026
“At least $140 million”
Other (NPHS, at-Home Solutions, OptiFreight … for FY2026
“26% to 28% growth”
Other (NPHS, at-Home Solutions, OptiFreight … for FY2026
“25% to 27% growth”
Interest and other for FY2026
“~$275 million”
Non-GAAP effective tax rate for FY2026
“22.0% - 24.0%”
Diluted weighted average shares outstanding for FY2026
“238 million to 240 million”
Share repurchases for FY2026
“~$750 million”
Capital expenditures for FY2026
“~$600 million”
Non-GAAP adjusted free cash flow for FY2026
“$2.75 billion to $3.25 billion”
Exhibit 99.1 · the passage around this item
… earlier in the release
Non-GAAP earnings per share $9.30 to $9.50 Pharmaceutical and Specialty Solutions segment: Revenue 11% to 13% growth Segment profit 11% to 13% growth Global Medical Products and Distribution segment: Revenue 2% to 4% growth Segment profit At least $140 million Other (NPHS, at-Home Solutions, OptiFreight Logistics): Revenue 26% to 28% growth Segment profit 25% to 27% growth Interest and other ~$275 million Non-GAAP effective tax rate 22.0% - 24.0% Diluted weighted average shares outstanding 238 million to 240 million Share repurchases ~$750 million Capital Expenditures ~$600 million Non-GAAP adjusted free cash flow $2.75 billion to $3.25 billion Bold indicates a change to the preliminary FY26 outlook provided in the Investor Day press release on June 12, 2025. The increase to non-GAAP diluted EPS reflects a benefit to net earnings of classifying the shares held by physicians and management of The Specialty Alliance as a liability as opposed to non-controlling interests within equity and increased contributions from the Pharmaceutical and Specialty Solutions segment and the growth businesses reported in Other. 3 Recent highlights • Cardinal Health hosted an Investor Day on June 12th, 2025 where management detailed the company's momentum, growth strategies and updated long-term value creation plans • Cardinal Health announced that the company entered into a definitive agreement to acquire Solaris Health, the country’s leading urology MSO with over 750 providers. Solaris Health will join the Specialty Alliance’s Urology Alliance and advances Cardinal Health’s multi-specialty growth strategy • Cardinal Health hosted its 33 rd a
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.